Presenting two clinical studies facilitated by the DeNovo® CTC scanning system:
Chaithanya Chelakkot, PhD, Genobio Corp. Scientific Advisor, GenoBioIntroducing the GenoCTC®, a novel CTC enrichment device, which relies on immune-magnetophoresis and microfluidics.
Presenting two clinical studies facilitated by the DeNovo® CTC scanning system:
– Feasibility study in advanced non-small cell lung cancer patients which demonstrated 94% CTC detection rate.
– Study evaluating EpCAM positive CTCs and c-MET positive CTCs in hormone receptor positive metastatic breast cancer patients (mBC).
Please join us to learn more about our exciting studies results. Link